Sandoz to invest €150 million in new antibiotics manufacturing technology in Europe over next three to five years, to be optimally prepared for future needs
Kundl, Austria further strengthens production for oral antibiotics while facility in Palafolls, Spain expands for sterile active pharmaceutical ingredients
Investment affirms long-term confidence in antibiotics strategy, delivering and building on published plans for European-based manufacturing network
https://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00English RSS Feedhttps://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pngEnglish RSS Feed2021-05-18 09:45:002021-05-18 09:45:00Sandoz announces plans to further strengthen its antibiotics manufacturing setup in Europe
Novartis has delivered 1 billion courses of antimalarial treatment, including 430 million pediatric treatments, largely at no profit since 1999
With other innovations, the Novartis artemisinin-based combination therapy (ACT) contributed to reduce malaria deaths by nearly half over the same timeframe1
Novartis continues to invest in research and development for next-generation antimalarials to combat the threat of artemisinin resistance
